This indicates that CARM1 inhibitors might work to restore normal gene expression; they will not work to reduce CARM1-enhanced PARylation; and they will prove detrimental when CARM1 levels are used as a marker of vulnerability of cancer cells to EZH2 inhibition. This evidence concerns the gene CARM1 and cancer.